Recent Progress in the Application of Nanotechnology for Prevention and Treatment of Human Papillomavirus Infection

• Crum CP , AbbottDW, QuadeBJ. Cervical cancer screening: from the Papanicolaou smear to the vaccine era. J. Clin. Oncol.21(Suppl. 10), 224s–230s (2003).
   PubMedGoogle Scholar
• Clifford GM , RanaRK, FranceschiS, SmithJS, GoughG, PimentaJM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev.14(5), 1157–1164 (2005).
   PubMed Web of Science ®Google Scholar
• Li N , FranceschiS, Howell-JonesR, SnijdersPJ, CliffordGM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer128(4), 927–935 (2011).
   PubMed Web of Science ®Google Scholar
• Chen D , McKayJD, CliffordGet al. Genome-wide association study of HPV seropositivity. Hum. Mol. Genet. doi:10.1093/hmg/ddr383 (2011) (Epub ahead of print).
   Google Scholar
• Barzon L , MilitelloV, PagniSet al. Distribution of human papillomavirus types in the anogenital tract of females and males. J. Med. Virol. 82(8), 1424–1430 (2010).
   PubMed Web of Science ®Google Scholar
• Alibegashvili T , CliffordGM, VaccarellaSet al. Human papillomavirus infection in women with and without cervical cancer in Tbilisi, Georgia. Cancer Epidemiol. 35(5), 465–470 (2011).
   PubMed Web of Science ®Google Scholar
• Bardin A , VaccarellaS, CliffordGMet al. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur. J. Cancer 44(4), 557–564 (2008).
   PubMed Web of Science ®Google Scholar
• Clifford GM , ShinHR, OhJKet al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol. Biomarkers Prev. 16(9), 1874–1879 (2007).
   PubMed Web of Science ®Google Scholar
• De Vuyst H , CliffordG, LiN, FranceschiS. HPV infection in Europe. Eur. J. Cancer45(15), 2632–2639 (2009).
   PubMed Web of Science ®Google Scholar
• Dondog B , CliffordGM, VaccarellaSet al. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol. Biomarkers Prev. 17(7), 1731–1738 (2008).
   PubMed Web of Science ®Google Scholar
• Hammouda D , CliffordGM, PallardySet al. Human papillomavirus infection in a population-based sample of women in Algiers, Algeria. Int. J. Cancer 128(9), 2224–2229 (2011).
   PubMed Web of Science ®Google Scholar
• Keita N , CliffordGM, KoulibalyMet al. HPV infection in women with and without cervical cancer in Conakry, Guinea. Br. J. Cancer 101(1), 202–208 (2009).
   PubMed Web of Science ®Google Scholar
• Li LK , DaiM, CliffordGMet al. Human papillomavirus infection in Shenyang City, People‘s Republic of China: a population-based study. Br. J. Cancer 95(11), 1593–1597 (2006).
   PubMed Web of Science ®Google Scholar
• Okolo C , FranceschiS, AdewoleIet al. Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infect. Agents Cancer 5(1), 24 (2010).
   PubMedGoogle Scholar
• Parkin DM , AlmonteM, BruniL, CliffordG, CuradoMP, PinerosM. Burden and trends of type-specific human papillomavirus infections and related diseases in the latin america and Caribbean region. Vaccine26(Suppl. 11), L1–L15 (2008).
   PubMed Web of Science ®Google Scholar
• Parkin DM , LouieKS, CliffordG. Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine26(Suppl. 12), M1–M16 (2008).
   PubMed Web of Science ®Google Scholar
• Raza SA , FranceschiS, PallardySet al. Human papillomavirus infection in women with and without cervical cancer in Karachi, Pakistan. Br. J. Cancer 102(11), 1657–1660 (2010).
   PubMed Web of Science ®Google Scholar
• Sherpa AT , CliffordGM, VaccarellaSet al. Human papillomavirus infection in women with and without cervical cancer in Nepal. Cancer Causes Control 21(3), 323–330 (2010).
   PubMed Web of Science ®Google Scholar
• Shi JF , QiaoYL, SmithJSet al. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine 26(Suppl. 12), M53–M59 (2008).
   PubMed Web of Science ®Google Scholar
• Vuyst HD , NdiranguG, MoodleyMet al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int. J. Cancer 131(4), 949–955 (2011).
   PubMed Web of Science ®Google Scholar
• Wu RF , DaiM, QiaoYLet al. Human papillomavirus infection in women in Shenzhen City, People‘s Republic of China, a population typical of recent Chinese urbanisation. Int. J. Cancer 121(6), 1306–1311 (2007).
   PubMed Web of Science ®Google Scholar
• Castlellsague X , Sde Sanjose S, Aguado T et al.HPV and Cervical Cancer in the World: 2007 Report. Elsevier, Amsterdam, The Netherlands (2007).
   Google Scholar
• Dunne EF , UngerER, SternbergMet al. Prevalence of HPV infection among females in the United States. JAMA 297(8), 813–819 (2007).
   PubMed Web of Science ®Google Scholar
• Evans MF , AdamsonCS, PapilloJL, St John TL, Leiman G, Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer106(5), 1054–1064 (2006).
   PubMed Web of Science ®Google Scholar
• WHO. Human Papillomavirus and Related Cancers (3rd Edition). WHO HPV Information Centre, London, UK (2010).
   Google Scholar
• Adelstein DJ , RodriguezCP. Human papillomavirus: changing paradigms in oropharyngeal cancer. Curr. Oncol. Rep.12(2), 115–120 (2010).
   PubMed Web of Science ®Google Scholar
• Allen CT , LewisJS Jr, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope120(9), 1756–1772 (2010).
   PubMed Web of Science ®Google Scholar
• Attner P , DuJ, NasmanAet al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int. J. Cancer 126(12), 2879–2884 (2010).
   PubMed Web of Science ®Google Scholar
• Auluck A , HislopG, BajdikC, PohC, ZhangL, RosinM. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer116(11), 2635–2644 (2010).
   PubMed Web of Science ®Google Scholar
• Badulescu F , CrisanA, BadulescuA, SchenkerM. Recent data about the role of human papillomavirus (HPV) in oncogenesis of head and neck cancer. Rom. J. Morphol. Embryol.51(3), 437–440 (2010).
   PubMed Web of Science ®Google Scholar
• Ang KK , HarrisJ, WheelerRet al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363(1), 24–35 (2010).
   PubMed Web of Science ®Google Scholar
• Burchell AN , WinerRL, De Sanjose S, Franco EL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine24(Suppl. 3), S3/52–61 (2006).
   Web of Science ®Google Scholar
• Pagliusi SR , DillnerJ, PawlitaM, QuintWG, WheelerCM, FergusonM. International Standard reagents for harmonization of HPV serology and DNA assays – an update. Vaccine24(Suppl. 3), 193–200 (2006).
   Web of Science ®Google Scholar
• Saslow D , CastlePE, CoxJTet al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J. Clin. 57(1), 7–28 (2007).
   PubMed Web of Science ®Google Scholar
• Davey DD , WoodhouseS, StyerP, StastnyJ, ModyD. Atypical epithelial cells and specimen adequacy: current laboratory practices of participants in the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. Arch. Pathol. Lab. Med.124(2), 203–211 (2000).
   PubMed Web of Science ®Google Scholar
• Insinga RP , GlassAG, RushBB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J. Obstet. Gynecol.191(1), 105–113 (2004).
   PubMed Web of Science ®Google Scholar
• Schiller JT , DayPM, KinesRC. Current understanding of the mechanism of HPV infection. Gynecol. Oncol.118(Suppl. 1), S12–S17 (2010).
   PubMedGoogle Scholar
• Woodman CB , CollinsSI, YoungLS. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer7(1), 11–22 (2007).
   PubMed Web of Science ®Google Scholar
• Gissmann L , PfisterH, Zur Hausen H. Human papilloma viruses (HPV): characterization of four different isolates. Virology76(2), 569–580 (1977).
   PubMed Web of Science ®Google Scholar
• Gissmann L , BoshartM, DurstM, IkenbergH, WagnerD, Zur Hausen H. Presence of human papillomavirus in genital tumors. J. Invest. Dermatol.83(Suppl. 1), 26s–28s (1984).
   PubMed Web of Science ®Google Scholar
• Durst M , GissmannL, IkenbergH, Zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl Acad. Sci. USA80(12), 3812–3815 (1983).
   PubMed Web of Science ®Google Scholar
• Gissmann L , Zur Hausen H. Partial characterization of viral DNA from human genital warts (Condylomata acuminata). Int. J. Cancer25(5), 605–609 (1980)
   PubMed Web of Science ®Google Scholar
• Hawley-Nelson P , VousdenKH, HubbertNL, LowyDR, SchillerJT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J.8(12), 3905–3910 (1989).
   PubMed Web of Science ®Google Scholar
• Walboomers JM , JacobsMV, ManosMMet al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• Zur Hausen H . Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer2(5), 342–350 (2002).
   PubMed Web of Science ®Google Scholar
• Zur Hausen H . Papillomaviruses in the causation of human cancers – a brief historical account. Virology384(2), 260–265 (2009).
   PubMed Web of Science ®Google Scholar
• Ferenczy A , BraunL, ShahKV. Human papillomavirus (HPV) in condylomatous lesions of cervix. Am. J. Surg. Pathol.5(7), 661–670 (1981).
   PubMed Web of Science ®Google Scholar
• Wright TC Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol.197(4), 346–355 (2007).
   PubMed Web of Science ®Google Scholar
• Lee Mortensen G , AdelerAL. Qualitative study of women‘s anxiety and information needs after a diagnosis of cervical dysplasia. Z. Gesundh. Wiss.18(5), 473–482 (2010).
   PubMedGoogle Scholar
• Langley PC . A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts. J. Med. Econ.13(1), 1–7 (2010).
   PubMedGoogle Scholar
• Lacey CJ , WoodhallSC, WikstromA, RossJ. 2012 European guideline for the management of anogenital warts. J. Eur. Acad. Dermatol. Venereol. doi:10.1111/j.1468-3083.2012.04493 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Pachman DR , BartonDL, ClaytonACet al. Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am. J. Obstet. Gynecol. (2011).
   PubMed Web of Science ®Google Scholar
• Gupta AK , CooperEA, AbramovitsW. Zyclara (imiquimod) cream, 3.75%. Skinmed8(4), 227–229 (2010).
   PubMedGoogle Scholar
• Bergman SJ , FergusonMC, SantanelloC. Interferons as therapeutic agents for infectious diseases. Infect. Dis. Clin. North Am.25(4), 819–834 (2011).
   PubMed Web of Science ®Google Scholar
• Yang J , PuYG, ZengZM, YuZJ, HuangN, DengQW. Interferon for the treatment of genital warts: a systematic review. BMC Infect. Dis.9, 156 (2009).
   PubMedGoogle Scholar
• Syed TA , CheemaKM, KhayyamiM, AhmadSA, AhmadSH, AhmadS. Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study. Dermatology191(2), 129–132 (1995).
   PubMed Web of Science ®Google Scholar
• Syed TA , AhmadpourOA, AhmadSA, AhmadSH. Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study. J. Dermatol.25(7), 429–433 (1998).
   PubMedGoogle Scholar
• Yliskoski M , CantellK, SyrjanenK, SyrjanenS. Topical treatment with human leukocyte interferon of HPV 16 infections associated with cervical and vaginal intraepithelial neoplasias. Gynecol. Oncol.36(3), 353–357 (1990).
   PubMed Web of Science ®Google Scholar
• Schneider A , PapendickU, GissmannL, De Villiers EM. Interferon treatment of human genital papillomavirus infection: importance of viral type. Int. J. Cancer40(5), 610–614 (1987).
   PubMed Web of Science ®Google Scholar
• Keay S , TengN, EisenbergM, StoryB, SellersPW, MeriganTC. Topical interferon for treating condyloma acuminata in women. J. Infect. Dis.158(5), 934–939 (1988).
   PubMed Web of Science ®Google Scholar
• Vesterinen E , MeyerB, PurolaE, CantellK. Treatment of vaginal flat condyloma with interferon cream. Lancet1(8369), 157 (1984).
   PubMedGoogle Scholar
• Vesterinen E , MeyerB, CantellK, PurolaE. Topical treatment of flat vaginal condyloma with human leukocyte interferon. Obstet. Gynecol.64(4), 535–538 (1984).
   PubMed Web of Science ®Google Scholar
• Syed TA , AhmadpourOA. Human leukocyte derived interferon-alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study. Int. J. STD AIDS9(12), 769–772 (1998).
   PubMed Web of Science ®Google Scholar
• Chakalova G , GanchevG. Local administration of interferon-alpha in cases of cervical intraepithelial neoplasia associated with human papillomavirus infection. J. BUON9(4), 399–402 (2004).
   PubMedGoogle Scholar
• Stanley MA . Genital human papillomavirus infections: current and prospective therapies. J. Gen Virol.93(Pt 4), 681–691 (2012).
   PubMed Web of Science ®Google Scholar
• D‘Abramo CM , ArchambaultJ. Small molecule inhibitors of human papillomavirus protein–protein interactions. Open Virol. J.5, 80–95 (2011).
   PubMedGoogle Scholar
• Foldvari M , BadeaI, KumarPet al. Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections. Curr. Drug Deliv. 8(3), 307–319 (2011).
   PubMed Web of Science ®Google Scholar
• Foldvari M . Biphasic vesicles: a novel topical drug delivery system. J. Biomed. Nanotechnol.6(5), 543–557 (2010).
   PubMed Web of Science ®Google Scholar
• Foldvari M , BadeaI, WettigSet al. Topical delivery of interferon alpha by biphasic vesicles: evidence for a novel nanopathway across the stratum corneum. Mol. Pharm. 7(3), 751–762 (2010).
   PubMed Web of Science ®Google Scholar
• Kurzeja R , BohmerG, SchneiderA. Clinical outcome of topical interferon alpha-2b cream in Phase II trial for LSIL/CIN patients. J. Cancer Ther.2, 203–208 (2011).
   Google Scholar
• Cichon G , KurzejaR, SchneiderA. Intravaginally administered interferon alpha-2b in patients with CIN1/2. 27th International Papillomavirus Conference and Clinical Workshop, 166, Berlin, Germany, 17–22 September 2011.
   Google Scholar
• Kaufmann AM , SchneiderA. New paradigm for prevention of cervical cancer. Eur. J. Obstet Gynecol. Reprod. Biol.130(1), 25–29 (2007).
   PubMed Web of Science ®Google Scholar
• Shi L , SingsHL, BryanJTet al. GARDASIL: prophylactic human papillomavirus vaccine development – from bench top to bed-side. Clin. Pharmacol. Ther. 81(2), 259–264 (2007).
   PubMed Web of Science ®Google Scholar
• Committee on Immunization Practices (ACIP). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory. Morb. Mortal Wkly Rep.59(20), 626–629 (2010).
   PubMedGoogle Scholar
• Deschuyteneer M , ElouahabiA, PlainchampDet al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum. Vaccin. 6(5), 407–419 (2010).
   PubMed Web of Science ®Google Scholar
• Frazer IH , LeggattGR, MattarolloSR. Prevention and treatment of papillomavirus-related cancers through immunization. Annu. Rev. Immunol.29, 111–138 (2011).
   PubMed Web of Science ®Google Scholar
• Chen XS , GarceaRL, GoldbergI, CasiniG, HarrisonSC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell5(3), 557–567 (2000).
   PubMed Web of Science ®Google Scholar
• Le Tallec D , DoucetD, ElouahabiA, HarvengtP, DeschuyteneerM, DeschampsM. Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum. Vaccin.5(7), 467–474 (2009).
   PubMed Web of Science ®Google Scholar
• Bishop B , DasguptaJ, KleinMet al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J. Biol. Chem. 282(43), 31803–31811 (2007).
   PubMed Web of Science ®Google Scholar
• Shank-Retzlaff ML , ZhaoQ, AndersonCet al. Evaluation of the thermal stability of Gardasil. Hum. Vaccin. 2(4), 147–154 (2006).
   PubMed Web of Science ®Google Scholar
• McCarthy MP , WhiteWI, Palmer-HillF, KoenigS, SuzichJA. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.J. Virol.72(1), 32–41 (1998).
   PubMed Web of Science ®Google Scholar
• Senger T , SchadlichL, TextorSet al. Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine 28(6), 1583–1593 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao Q , ModisY, HighKet al. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol. J. 9, 52 (2012).
   PubMed Web of Science ®Google Scholar
• Widdice LE , BernsteinDI, LeonardAC, MarsoloKA, KahnJA. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics127(1), 77–84 (2011).
   PubMed Web of Science ®Google Scholar
• Beard K . Reducing the rate of cervical cancer: ethical challenges in public health. J. Natl Black Nurses Assoc.21(2), 39–43 (2010).
   PubMedGoogle Scholar
• National, state, and local area vaccination coverage among adolescents aged 13–17 years – United States, 2009. Morb. Mortal Wkly Rep.59(32), 1018–1023 (2010).
   PubMedGoogle Scholar
• Ma B , XuY, HungCF, Wu T-C. HPV and therapeutic vaccines: where are we in 2010? Curr. Cancer Ther. Rev.6, 81–103 (2010).
   Google Scholar
• Stanley M . HPV vaccines: are they the answer? Br. Med. Bull.88(1), 59–74 (2008).
   PubMed Web of Science ®Google Scholar
• Stanley M . Prospects for new human papillomavirus vaccines. Curr. Opin. Infect. Dis.23(1), 70–75 (2010).
   PubMed Web of Science ®Google Scholar
• Doorbar J . Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond.)110(5), 525–541 (2006).
   PubMed Web of Science ®Google Scholar
• Hendrix SL . Assessing human papillomavirus vaccine efficacy and safety. J. Am. Osteopath. Assoc.108(4 Suppl. 2), S8–S12 (2008).
   PubMedGoogle Scholar
• Schiller JT , DaviesP. Delivering on the promise: HPV vaccines and cervical cancer. Nat. Rev. Microbiol.2(4), 343–347 (2004).
   PubMed Web of Science ®Google Scholar

Websites

• HPVinfo. Incidence and prevalence of HPV in Canada. www.hpvinfo.ca/health-care-professionals/what-is-hpv/incidence-and-prevalence-of-hpv-in-canada
   Google Scholar
• Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2006. www.cdc.gov/std/treatment/2006/HPV.htm
   Google Scholar
• WHO. Reproductive health. www.who.int/reproductivehealth/publications/cancers/RHR_08_14/en/index.html
   Google Scholar
• Morbidity and Mortality Weekly Report. Volume 59, No. RR-12. www.cdc.gov/mmwr
   Google Scholar
• Merck. Product monograph. www.merckfrosst.ca/assets/en/pdf/products/Intron_A-PM_E.pdf
   Google Scholar